MedTrace Logo

Recurrent Events After Percutaneous Coronary INterventio for ACS

NCT03675347 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2018-09-18

No results posted yet for this study

Summary

Patients undergoing PCI for ACS are exposed to a significant ischemic and bleeding risk.

The aim of our study is instead to analyze in detail the rates of recurrent events, but also their predictors and impact on outcomes, in a population of unselected real life patients treated with PCI for ACS discharged on either Clopidogrel, Prasugrel or Ticagrelor who already experienced an adverse event during the first year of follow up.

Conditions

Interventions

OTHER

angioplasty

angioplasty

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Principal Investigators

  • biole carloalberto, doctor · Molinette

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03675347 on ClinicalTrials.gov